UK Markets open in 7 hrs 7 mins

ERYTECH Pharma S.A. (0QSS.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.1289-0.0812 (-6.71%)
At close: 04:47PM BST
Full screen
Loading interactive chart…
  • Globe Newswire

    ERYTECH to Present at the H.C. Wainwright Global Investment Conference

    ERYTECH to Present at the H.C. Wainwright Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26

  • Globe Newswire

    Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022

    Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2

  • Globe Newswire

    ERYTECH Provides Business and Financial Update for the First Quarter of 2022

    ERYTECH Provides Business and Financial Update for the First Quarter of 2022 Conference call and webcast on Friday, May 13, 2022at 8:30am EDT / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 millionProgress towards seeking approval of GRASPA® (BLA) for the treatment of acute lymphoblastic leukemia (ALL) patients with hypersensitivity to pegylated asparaginase Cash and cash equivalents of EUR 25.1 million (USD 27.9 million) at the end